Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05274178 · ClinicalTrials.gov registry record · NA
Effect of Hearing Aid Labeling on Speech Understanding Measures
A NA study of Hearing Loss, sponsored by Sonova.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05274178: Completed NA study of Hearing Loss, sponsored by Sonova.
NCT05274178 is a NA study of Hearing Loss that has completed, run by Sonova. The registered enrollment target is 20 participants, below the 6,121-participant average among 58 other Hearing Loss trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05274178, a NA study of Hearing Loss, has completed, sponsored by Sonova.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
New and experienced hearing aid users will be fit with two hearing devices. One will be labeled as an OTC (Over-The-Counter) device, the other will be labeled as a Prescriptive (i.e. professionally fit) device. Both devices will be generically programmed for a mild to moderate hearing loss. An objective speech in noise test will be completed with both devices.
Primary Outcome
A speech in noise test in which participant repeats sentences in variable levels of background noise. Test result is reported as the signal to noise level at which participant can repeat 50% of the words correctly. A lower score/dB SNR (decibel Signal to Noise Ratio) level indicates better speech in noise perception. For example, a score of 0 dB would indicate that the participant can repeat 50% of the words presented when the speech signal and the noise are presented at the same level. A score
Conditions Studied
Interventions
- DEVICE Audeo P hearing aid labeled as "Prescriptive"
- DEVICE Audeo P hearing aid labeled as "OTC"
Study Locations (1)
Illinois
- Sonova US - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-05-26 |
| Est. Completion | 2022-06-16 |
| Phase | NA |
What the finished NCT05274178 record still lists
NCT05274178 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 6,121-participant average among 58 other Hearing Loss trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Hearing Loss appearing as the primary indexed condition, and to 2 interventions - of which Audeo P hearing aid labeled as "Prescriptive" is the first listed.
NCT05274178 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05274178 about?
NCT05274178 is a clinical study titled "Effect of Hearing Aid Labeling on Speech Understanding Measures". New and experienced hearing aid users will be fit with two hearing devices. One will be labeled as an OTC (Over-The-Counter) device, the other will be labeled as a Prescriptive (i.e. professionally fit) device. Both devices will be generically programmed for a mild to moderate hearing loss. An objec...
What is the current status of trial NCT05274178?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2022-05-26. Estimated completion is 2022-06-16.
What conditions does trial NCT05274178 study?
This clinical trial studies the following conditions: Hearing Loss.
What interventions are being tested in trial NCT05274178?
The interventions under investigation include: Audeo P hearing aid labeled as "Prescriptive" (DEVICE), Audeo P hearing aid labeled as "OTC" (DEVICE).
Who is sponsoring clinical trial NCT05274178?
This trial is sponsored by Sonova, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05274178 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hearing Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05274178's enrollment target sits among peer trials
20 57th of 58 higher than 1 of 58 other Hearing Loss trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hearing Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Access and Affordability of Adult Hearing Healthcare
RECRUITING · NA
-
AI Noise Reduction in Phonak Hearing Aids
RECRUITING · NA
-
Investigation of a Device to Deliver Intra-Operative Therapeutic Hypothermia for Hearing Preservation in Cochlear Implantation
RECRUITING · NA
-
Auditory-Cognitive Training to Optimize Outcomes for Older CI Users
RECRUITING · NA
-
Innovations in Hearing Accessibility and Technology (IHAT) Study
RECRUITING · NA
-
Clinical Utility of Residual Hearing in the Cochlear Implant Ear
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI